612 related articles for article (PubMed ID: 16322897)
1. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
2. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
3. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
5. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells.
Luker KE; Pica CM; Schreiber RD; Piwnica-Worms D
Cancer Res; 2001 Sep; 61(17):6540-7. PubMed ID: 11522652
[TBL] [Abstract][Full Text] [Related]
8. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
10. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
11. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ
Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928
[TBL] [Abstract][Full Text] [Related]
12. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
13. The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data.
Hembruff SL; Villeneuve DJ; Parissenti AM
Anal Biochem; 2005 Oct; 345(2):237-49. PubMed ID: 16139235
[TBL] [Abstract][Full Text] [Related]
14. [Screening the differential expression of adriamycin-resistance related genes of breast cancer by cDNA microarray].
Peng H; Yang HW; Song LW; Zhou Z
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(25):1745-8. PubMed ID: 19862977
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
16. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
17. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
Duan Z; Feller AJ; Penson RT; Chabner BA; Seiden MV
Clin Cancer Res; 1999 Nov; 5(11):3445-53. PubMed ID: 10589757
[TBL] [Abstract][Full Text] [Related]
18. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
19. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells.
Kars MD; Işeri OD; Gündüz U
Eur J Pharmacol; 2011 Apr; 657(1-3):4-9. PubMed ID: 21320484
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]